Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 20:09:53 Source:worldViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Shohei Ohtani's first walk
Next:The fightback begins: Boss of London's Queen Mary University tells pro
You may also like
- Investigators return to Long Island home of Gilgo Beach serial killing suspect
- Unusual floods in eastern Congo causing hardship to almost half a million people, WFP says
- Australian judge extends ban on X sharing video of Sydney bishop's stabbing
- Bodies of 2 backcountry skiers buried by Utah avalanche recovered from mountain, names released
- Not so Cool Britannia! Noel Gallagher gives damning verdict on Keir Starmer
- A bus plunges off a bridge in the Russian city of St. Petersburg, killing 3 and injuring 6 others
- Who ARE the real
- Lithuania holds a presidential vote as anxieties rise in the Baltics over Russia and war in Ukraine
- Everybody may love Raymond, but Ray Romano loves Peter Boyle